IDENTIFICATION DETAILS
|
Name : |
ONTOP PHARMACEUTICALS PRIVATE LIMITED (w.e.f.22.09.2010) |
|
|
|
|
Formerly Known
As : |
ONTOP PHARMACEUTICALS LIMITED |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2013 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
BLRO01039D BLRO00203A |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACO2536N |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
No. of Employees
: |
220 (Approximately) (Including Contract Workers) |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Formulation. |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit |
|
|
|
|
Purchasing : |
Cash and Credit |
GENERAL INFORMATION
|
Suppliers : |
¨ Mahadev Medical
Agency ¨ Reddy
Pharmaceuticals Limited |
|||||||||||||||
|
|
|
|||||||||||||||
|
Customers : |
Wholesalers and Retailers ¨ Glenmark
Pharmaceuticals Limited ¨ Centure
Pharmaceuticals Limited |
|||||||||||||||
|
|
|
|||||||||||||||
|
No. of Employees : |
220 (Approximately) (Including Contract Workers) |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
Karnataka Bank Limited, P.B.No.599, |
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
S. P. Krishnamurthy And Company Chartered Accountants |
|
Address : |
No. 36, 1st Floor, 4th Main, Vyalikaval, Bangalore –
560003, Karnataka, India |
|
Tel. No.: |
91-80-23312859 |
|
Mobile No.: |
91-9341228317 |
|
E-Mail : |
|
|
PAN
No. : |
ABCOK7127K |
|
|
|
|
Associate : |
Systopic Laboratories Private Limited |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2013
|
Names of Shareholders |
No. of Shares |
% of Shares Held |
|
Abhishek Dutta |
539300 |
47.84 |
|
Sanju Dutt |
587902 |
52.16 |
|
|
|
|
|
Total |
1127202 |
100.00 |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
11.272 |
11.272 |
11.272 |
|
(b) Reserves & Surplus |
75.190 |
59.513 |
42.628 |
|
(c) Money received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
86.462 |
70.785 |
53.900 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
0.000 |
0.000 |
2.350 |
|
(b) Deferred tax liabilities (Net) |
13.222 |
12.392 |
12.906 |
|
(c) Other long
term liabilities |
0.000 |
0.000 |
0.000 |
|
(d) long-term
provisions |
5.230 |
3.805 |
3.009 |
|
Total Non-current
Liabilities (3) |
18.452 |
16.197 |
18.265 |
|
|
|
|
|
|
(4)
Current Liabilities |
|
|
|
|
(a)
Short term borrowings |
13.576 |
7.014 |
22.496 |
|
(b)
Trade payables |
56.699 |
36.719 |
42.941 |
|
(c)
Other current liabilities |
4.369 |
21.668 |
41.326 |
|
(d) Short-term
provisions |
0.000 |
1.696 |
0.000 |
|
Total Current
Liabilities (4) |
74.644 |
67.097 |
106.763 |
|
|
|
|
|
|
TOTAL |
179.558 |
154.079 |
178.928 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1)
Non-current assets |
|
|
|
|
(a) Fixed
Assets |
|
|
127.199 |
|
(i)
Tangible assets |
117.373 |
118.704 |
0.000 |
|
(ii)
Intangible Assets |
0.000 |
0.000 |
0.000 |
|
(iii)
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
(iv)
Intangible assets under development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
0.000 |
0.000 |
0.000 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
1.414 |
|
(d) Long-term Loan and Advances |
1.373 |
1.614 |
0.000 |
|
(e) Other
Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total Non-Current
Assets |
118.746 |
120.318 |
128.613 |
|
|
|
|
|
|
(2)
Current assets |
|
|
|
|
(a)
Current investments |
0.000 |
0.000 |
0.000 |
|
(b)
Inventories |
43.553 |
23.009 |
32.256 |
|
(c)
Trade receivables |
11.912 |
4.531 |
3.959 |
|
(d) Cash
and cash equivalents |
0.053 |
0.031 |
0.014 |
|
(e)
Short-term loans and advances |
1.059 |
1.107 |
6.510 |
|
(f)
Other current assets |
4.235 |
5.083 |
7.576 |
|
Total
Current Assets |
60.812 |
33.761 |
50.315 |
|
|
|
|
|
|
TOTAL |
179.558 |
154.079 |
178.928 |
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
398.306 |
379.569 |
292.068 |
|
|
|
Other Income |
1.961 |
0.006 |
0.026 |
|
|
|
TOTAL |
400.267 |
379.575 |
292.094 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
TOTAL |
370.166 |
347.468 |
263.351 |
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION |
30.101 |
32.107 |
28.743 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
7.003 |
6.875 |
6.422 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
23.098 |
25.232 |
22.321 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
7.421 |
8.347 |
8.537 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
15.677 |
16.885 |
13.784 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS YEARS’
BALANCE BROUGHT FORWARD |
57.160 |
40.275 |
26.491 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
72.837 |
57.160 |
40.275 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
13.91 |
14.98 |
12.23 |
|
|
Particulars |
|
|
31.03.2014 |
|
|
|
|
|
|
Sales Turnover (Approximately) |
|
|
600.000 |
|
|
|
|
|
The above information has been parted by Mr. Sreedhar
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (45) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
RBI DEFAULTERS LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
LOCATIONS
|
Registered Office/ Factory : |
9-D, Bommasandra Industrial Area, Hosur Road, Bangalore – 562158,
Karnataka, India |
|
Tel. No.: |
91-80-27833435 |
|
Fax No.: |
91-80-27831360 |
|
E-Mail : |
|
|
Area : |
2 Acre |
|
Location : |
Owned |
|
|
|
|
Marketing Office : |
G-1, Satya Mansion, Commercial Complex, Ranjit Nagar, New Delhi,
India |
|
Location : |
Owned |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.